Sexually transmitted diseases may be diagnosed by OD first

Article

Optometrists and infectious disease specialists can unite to address what has been called a "hidden epidemic" with enormous health and economic consequences-sexually transmitted diseases.

Optometrists and infectious disease specialists can unite to address what has been called a "hidden epidemic" with enormous health and economic consequences: sexually transmitted diseases (STDs).

History tells the story

"If you suspect HIV, order the appropriate laboratory testing, since many of these retinal vasculopathies look the same," Dr. Pelino added.

In a joint presentation on inflammatory retinal and choroidal disorders at the annual SECO meeting, Dr. Pelino's colleague, Joseph J. Pizzimenti, OD, FAAO, told clinicians that optic neuropathy can be the presenting overall sign of HIV.

"Keep this in mind when you identify a patient with disk edema, for example, and need to establish the cause," said Dr. Pizzimenti, who is associate professor, Nova Southeastern University College of Optometry, Fort Lauderdale, FL.

When HIV is mentioned in the patient history, optometrists should ask about viral load and CD4 count, find out if the patient is taking highly active antiretroviral therapy (HAART), and communicate ocular findings to the patient's primary care physician, often an infectious disease specialist. While HAART therapy is a lifesaving cocktail for many HIV patients, its side effects can include immune-recovery uveitis, a chronic intraocular disorder with symptoms of decreased vision and floaters. Clinically, it can present with anterior uveitis, epiretinal membrane formation, macular edema, and vitritis.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
© 2025 MJH Life Sciences

All rights reserved.